Document
Academic Article
RDF description of Acalabrutinib-obinutuzumab improves survival vs chemoimmunotherapy in treatment-naive CLL in the 6-year follow-up of ELEVATE-TN - http://irises.unisr.it/resource/item/218923
Generically Dependent Continuant
Article
Information Content Entity
Acalabrutinib-obinutuzumab improves survival vs chemoimmunotherapy in treatment-naive CLL in the 6-year follow-up of ELEVATE-TN